Cocrystal Pharma Stock Analysis
COCP Stock | USD 1.64 0.05 2.96% |
Cocrystal Pharma is undervalued with Real Value of 3.25 and Target Price of 8.33. The main objective of Cocrystal Pharma stock analysis is to determine its intrinsic value, which is an estimate of what Cocrystal Pharma is worth, separate from its market price. There are two main types of Cocrystal Pharma's stock analysis: fundamental analysis and technical analysis.
The Cocrystal Pharma stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Cocrystal Pharma is usually not traded on Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day, Juneteenth Holiday, Independence Day, Labour Day, Thanksgiving Day, Christmas Day, New Year 's Day. Cocrystal Stock trading window is adjusted to America/New York timezone.
Cocrystal | Build AI portfolio with Cocrystal Stock |
Cocrystal Stock Analysis Notes
About 36.0% of the company shares are held by company insiders. The book value of Cocrystal Pharma was currently reported as 0.72. The company has Price/Earnings (P/E) ratio of 193.33. Cocrystal Pharma recorded a loss per share of 1.56. The entity last dividend was issued on the 24th of January 2018. The firm had 1:12 split on the 11th of October 2022. Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious andor chronic viral diseases. Cocrystal Pharma, Inc. has a license and research collaboration agreement with Merck Sharp Dohme Corp. to discover and develop proprietary influenza AB antiviral agents a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections and drug discovery collaboration with HitGen and InterX Inc. Cocrystal Pharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 13 people. For more info on Cocrystal Pharma please contact CPA CPA at 877 262 7123 or go to https://www.cocrystalpharma.com.Cocrystal Pharma Investment Alerts
Cocrystal Pharma may become a speculative penny stock | |
Cocrystal Pharma had very high historical volatility over the last 90 days | |
Cocrystal Pharma has high likelihood to experience some financial distress in the next 2 years | |
Net Loss for the year was (17.5 M) with loss before overhead, payroll, taxes, and interest of (10.95 M). | |
Cocrystal Pharma currently holds about 51.03 M in cash with (16.48 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.28, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
Cocrystal Pharma has a poor financial position based on the latest SEC disclosures | |
Roughly 36.0% of the company shares are held by company insiders | |
Latest headline from gurufocus.com: Cocrystal Pharma to Present Data from Phase 1 Study of First-in-Class Norovirus Protease ... |
Cocrystal Pharma Upcoming and Recent Events
3rd of April 2024 Upcoming Quarterly Report | View | |
20th of May 2024 Next Financial Report | View | |
31st of December 2023 Next Fiscal Quarter End | View | |
3rd of April 2024 Next Fiscal Year End | View | |
30th of September 2023 Last Quarter Report | View | |
31st of December 2022 Last Financial Announcement | View |
Cocrystal Largest EPS Surprises
Earnings surprises can significantly impact Cocrystal Pharma's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
---|---|---|---|---|---|---|---|
2024-08-14 | 2024-06-30 | -0.48 | -0.53 | -0.05 | 10 | ||
2022-05-11 | 2022-03-31 | -0.42 | -0.48 | -0.06 | 14 | ||
2021-08-16 | 2021-06-30 | -0.42 | -0.48 | -0.06 | 14 |
Cocrystal Stock Institutional Investors
Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Shares | Citadel Advisors Llc | 2025-03-31 | 10 K | Bank Of America Corp | 2025-03-31 | 9 K | Morgan Stanley - Brokerage Accounts | 2025-03-31 | 5.9 K | Tower Research Capital Llc | 2025-03-31 | 2 K | Northwestern Mutual Wealth Management Co | 2025-03-31 | 817 | Clean Yield Group Inc | 2025-06-30 | 418 | Mccormack Advisors International | 2025-03-31 | 237 | Jpmorgan Chase & Co | 2025-03-31 | 104 | Nvwm, Llc | 2025-03-31 | 84.0 | Vanguard Group Inc | 2025-03-31 | 275.7 K | Renaissance Technologies Corp | 2025-03-31 | 125.6 K |
Cocrystal Market Capitalization
The company currently falls under 'Micro-Cap' category with a current market capitalization of 16.69 M.Cocrystal Profitablity
Last Reported | Projected for Next Year | ||
Return On Tangible Assets | (1.30) | (1.37) | |
Return On Capital Employed | (1.62) | (1.70) | |
Return On Assets | (1.30) | (1.37) | |
Return On Equity | (1.84) | (1.75) |
Management Efficiency
Cocrystal Pharma has return on total asset (ROA) of (0.5396) % which means that it has lost $0.5396 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.0605) %, meaning that it created substantial loss on money invested by shareholders. Cocrystal Pharma's management efficiency ratios could be used to measure how well Cocrystal Pharma manages its routine affairs as well as how well it operates its assets and liabilities. As of 07/21/2025, Return On Tangible Assets is likely to drop to -1.37. In addition to that, Return On Capital Employed is likely to drop to -1.7. At this time, Cocrystal Pharma's Total Current Liabilities is relatively stable compared to the past year. As of 07/21/2025, Non Current Liabilities Other is likely to grow to about 366.4 K, while Liabilities And Stockholders Equity is likely to drop slightly above 12.8 M.Last Reported | Projected for Next Year | ||
Book Value Per Share | 0.94 | 0.89 | |
Tangible Book Value Per Share | 0.94 | 0.98 | |
Enterprise Value Over EBITDA | (0.72) | (0.75) | |
Price Book Value Ratio | 2.16 | 2.05 | |
Enterprise Value Multiple | (0.72) | (0.75) | |
Price Fair Value | 2.16 | 2.05 | |
Enterprise Value | 88.6 M | 154.1 M |
Cocrystal Pharma showcases strong leadership that adapts to market changes and drives innovation. Our analysis explores how this adaptability affects the stock's investment appeal.
Technical Drivers
As of the 21st of July, Cocrystal Pharma shows the risk adjusted performance of 0.0937, and Mean Deviation of 3.18. Cocrystal Pharma technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.Cocrystal Pharma Price Movement Analysis
The output start index for this execution was twenty-nine with a total number of output elements of thirty-two. The Simple Moving Average indicator is calculated by adding the closing price of Cocrystal Pharma for a given number of time periods and then dividing this total by the number of time periods. It is used to smooth out Cocrystal Pharma short-term fluctuations and highlight longer-term trends or cycles.
Cocrystal Pharma Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Cocrystal Pharma insiders, such as employees or executives, is commonly permitted as long as it does not rely on Cocrystal Pharma's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Cocrystal Pharma insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Cocrystal Pharma Outstanding Bonds
Cocrystal Pharma issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Cocrystal Pharma uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Cocrystal bonds can be classified according to their maturity, which is the date when Cocrystal Pharma has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
MPLX LP 4125 Corp BondUS55336VAK61 | View | |
MPLX LP 52 Corp BondUS55336VAL45 | View | |
BNP Paribas FRN Corp BondUSF1R15XK367 | View | |
Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
Valero Energy Partners Corp BondUS91914JAA07 | View |
Cocrystal Pharma Predictive Daily Indicators
Cocrystal Pharma intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Cocrystal Pharma stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Cocrystal Pharma Forecast Models
Cocrystal Pharma's time-series forecasting models are one of many Cocrystal Pharma's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Cocrystal Pharma's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About Cocrystal Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how Cocrystal Pharma prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Cocrystal shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Cocrystal Pharma. By using and applying Cocrystal Stock analysis, traders can create a robust methodology for identifying Cocrystal entry and exit points for their positions.
Last Reported | Projected for Next Year | ||
Pretax Profit Margin | (5.51) | (5.78) | |
Operating Profit Margin | (5.47) | (5.75) | |
Net Loss | (5.51) | (5.79) | |
Gross Profit Margin | 0.79 | 0.83 |
Current Cocrystal Analysis - Recommendations
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Cocrystal analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Cocrystal analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target Price | Advice | # of Analysts | |
8.33 | Strong Buy | 2 | Odds |
Most Cocrystal analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Cocrystal stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Cocrystal Pharma, talking to its executives and customers, or listening to Cocrystal conference calls.
Cocrystal Stock Analysis Indicators
Cocrystal Pharma stock analysis indicators help investors evaluate how Cocrystal Pharma stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Cocrystal Pharma shares will generate the highest return on investment. By understating and applying Cocrystal Pharma stock analysis, traders can identify Cocrystal Pharma position entry and exit signals to maximize returns.
Begin Period Cash Flow | 26.4 M | |
Common Stock Shares Outstanding | 10.2 M | |
Total Stockholder Equity | 9.5 M | |
Total Cashflows From Investing Activities | -8000.00 | |
Property Plant And Equipment Net | 1.8 M | |
Cash And Short Term Investments | 9.9 M | |
Cash | 9.9 M | |
Accounts Payable | 1.5 M | |
Net Debt | -8.1 M | |
50 Day M A | 1.5582 | |
Total Current Liabilities | 2.4 M | |
Other Operating Expenses | 17.9 M | |
Non Current Assets Total | 1.9 M | |
Non Currrent Assets Other | 29 K | |
Stock Based Compensation | 643 K |
Additional Tools for Cocrystal Stock Analysis
When running Cocrystal Pharma's price analysis, check to measure Cocrystal Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cocrystal Pharma is operating at the current time. Most of Cocrystal Pharma's value examination focuses on studying past and present price action to predict the probability of Cocrystal Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cocrystal Pharma's price. Additionally, you may evaluate how the addition of Cocrystal Pharma to your portfolios can decrease your overall portfolio volatility.